WuXi Biologics awarded for sustainability and digital transformation
WuXi Biologics has received the Jade Award at The Asset Corporate Sustainability Leadership Awards 2026, recognizing the company's efforts in ESG and digital process integration.
Contract research and manufacturing organization WuXi Biologics has been named a recipient of the Jade Award at the 2026 The Asset Corporate Sustainability Leadership Awards. The recognition highlights the company's progress in environmental, social, and governance (ESG) reporting and implementation.
In addition to the primary accolade, the firm was recognized as "Best in Transition" for its operations in Hong Kong. This specific award acknowledges the company's efforts to integrate digital technologies into its production workflows while transitioning toward sustainable manufacturing practices.
As pharmaceutical contract development and manufacturing organizations (CDMOs) face increased regulatory and investor pressure regarding their environmental footprint, such benchmarks serve to evaluate industry progress. The awards underscore WuXi Biologics' strategy to align its operational development with current sustainability standards.